Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 7/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2313665 | 0.70 | SCD (0.56) | KMT2AMEN1NOTUMMAPTALDH1A1 | |
| SCHEMBL3061575 | 0.65 | KMT2A (0.41) | KMT2AMEN1NOTUMMAPTALDH1A1 | |
| SCHEMBL3071934 | 0.65 | NOTUM (0.43) | KMT2AMEN1NOTUMALDH1A1KDM4E | |
| SCHEMBL22124413 | 0.64 | NPC1 (0.37) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL10203103 | 0.63 | KMT2A (0.52) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL10203105 | 0.61 | GPR139 (0.40) | KMT2AMEN1LMNATSHRSMN1; SMN2 | |
| SCHEMBL16063128 | 0.60 | NOTUM (1.00) | KMT2AMEN1NOTUMMAPTALDH1A1 | |
| SCHEMBL27090193 | 0.59 | NOTUM (0.81) | KMT2AMEN1NOTUMMAPTALDH1A1 | |
| SCHEMBL516179 | 0.59 | ALDH1A1 (0.65) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL9808080 | 0.59 | ALDH1A1 (0.62) | KMT2AMEN1MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065227-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-03-15 | — | — | US | claimed |
| US-8088792-B2 | Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | claimed |
| EP-2268637-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | Gilead Sciences, Inc. (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009137201-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2009-11-12 | — | — | WO | claimed |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-10-08 | — | — | US | claimed |
| US-20120065227-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8088792-B2 | Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2268637-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | Gilead Sciences, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009137201-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065227-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, FASN | KMT2A 1899/4885MEN1 4716/4885NOTUM 127/4885 |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, FASN | KMT2A 1899/4885MEN1 4716/4885NOTUM 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.